Holen Sie sich die Stockscreener-App
8.70
0.11%
-0.01
Handel nachbörslich:
8.70
Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - Investing News Network
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application - marketscreener.com
Satellos Bioscience Inc. - Baystreet.ca
Stocks in play: Satellos Bioscience Inc. - ca.finance.yahoo.com
Satellos Receives FDA Clearance to Study Forazapadin in FSHD - Yahoo Finance
Satellos stock jumps after FDA clears FSHD trial for forazapadin - Yahoo Finance
Satellos stock jumps after FDA clears FSHD trial for forazapadin By Investing.com - Investing.com Australia
Satellos receives FDA clearance for FSHD drug trial - Investing.com
Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding - TipRanks
Satellos Bioscience Inc. (MSLE) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA clears a Satellos (MSLE) drug study for a disease affecting an estimated 800,000 people worldwide. - Stock Titan
Satellos receives FDA clearance for FSHD drug trial By Investing.com - Investing.com Canada
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - Caledon Enterprise
Satellos Bioscience Inc.(NasdaqGM: MSLE) added to S&P Global BMI Index - marketscreener.com
Satellos at H.C. Wainwright conference: DMD drug aims wider - Investing.com
Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress - TipRanks
Satellos Bioscience Announces Four Poster Presentations at the 2026 World Muscle Society Congress - Quiver Quantitative
Cash runway through 2027 backs Satellos (MSLE) muscle disease trials - Stock Titan
WHY Draganfly (CN:DPRO), Eco (Atlantic) Oil & Gas (TSXV:EOG), Mayfair Gold (TSXV:MFG), Satellos Bioscience (TSX:MSCL) and Foraco International SA (TSX:FAR) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
Satellos Bioscience Stock Faces Downside Pressure as Clinical Expectations Rise: Is Correction Risk Building? - kalkine.ca
Satellos Bioscience Stock Drops 5.24%: Is TSX:MSCL Facing a Sentiment-Driven Correction Ahead of Key Clinical Catalysts? - kalkine.ca
What's Going On With Satellos Bioscience Inc. Stock Friday? - Wealth Awesome
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
Satellos Bioscience (TSX:MSCL) Gains Momentum as Clinical Progress and Regenerative Medicine Potential Drive Investor Optimism - kalkine.ca
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 - Investing News Network
Satellos at Cantor healthcare conference: pipeline nears key data - Investing.com
Satellos at Cantor healthcare conference: pipeline nears key data By Investing.com - Investing.com UK
MSCL: Phase II trials of forazapadin show early promise in muscle regeneration, with pivotal data expected soon - TradingView
Satellos Bioscience is facing clinical execution risks—can it regain investor confidence and turn sentiment around? - kalkine.ca
Satellos assigns INN forazapadin to DMD drug candidate By Investing.com - Investing.com Canada
Satellos assigns INN forazapadin to DMD drug candidate - Investing.com
Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance - TipRanks
New muscle disease pill from Satellos Bioscience (MSLE) nears key Duchenne trial readout - Stock Titan
A muscle disease treatment candidate gets a new global name: forazapadin - Stock Titan
Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Did Satellos Bioscience (TSX:MSCL) Surge 7.43% on 31 August 2026? - kalkine.ca
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences - TipRanks
Satellos to Participate in Upcoming Investor Conferences - The Manila Times
Satellos cash runway through 2027, Phase 2 DMD | MSLE SEC FilingForm 6-K - Stock Titan
Satellos Bioscience (TSX:MSCL) Rises 7.43% as Duchenne Clinical Progress and Upcoming Data Catalysts Lift Investor Optimism - kalkine.ca
Satellos Bioscience Stock Falls 7.42% as Clinical-Stage Risk and Development Uncertainty Pressure Sentiment - kalkine.ca
Satellos Bioscience Inc. (TSX:MSCL) Falls 7.42% as Biotech Volatility and Clinical Development Risks Pressure Investor Confidence - kalkine.ca
LifeSci Capital Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Satellos Bioscience (MSLE) Slides Nearly 10% in High-Volume Biotech SelloffCalendar Spread Trade - vinanet.vn
Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE - marketbeat.com
Could Satellos Bioscience (TSX:MSCL) Redefine Muscle Regeneration? - Kalkine Media
LifeSci Capital Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $22 - Moomoo
LifeSci Capital Initiates Satellos Bioscience at Outperform - Yahoo Finance
Satellos Bioscience Stock Under Pressure as Biotech Volatility Raises Correction Risk - kalkine.ca
Satellos (MSLE) Stock: Ends Higher by 0.59% at $10.15 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest ReadingMonthly Profile - vinanet.vn
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
Why Satellos Bioscience Inc. stock is gaining today - wealthawesome.com
Satellos Bioscience (MSLE) Institutional Ownership 2026 - MarketBeat
Satellos Bioscience Stock Drops 3.39% as Investors Weigh Duchenne Muscular Dystrophy Therapy, Clinical Development and Biotech Risk - kalkine.ca
Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
HC Wainwright Reaffirms Buy Rating for Satellos Bioscience (NASDAQ:MSLE) - MarketBeat
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Satellos Bioscience Inc. MSCL Earnings Miss Estimates by 37.0% - Wealth Awesome
Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M - Streetwise Reports
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility - TipRanks
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):